

✔ Free access

1,060 44 0
Views CrossRef citations to date Altmetric

Listen

ORIGINAL RESEARCH

Exercise Testing in Severe Emphysema: Association with Quality of Life and Lung Function

Cynthia D. Brown, Joshua O. Benditt, Frank C. Sciurba, Shing M. Lee, Gerard J. Criner, Zab Mosenifar, ... show all

Pages 117-124 | Published online: 02 Jul 2009

🗨️ Cite this article 🔗 <https://doi.org/10.1080/15412550801941265>

📄 Full Article 📊 Figures & data 📖 References 🗨️ Citations 📊 Metrics

📄 Reprint

We Care About Your Privacy

We and our 907 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

...

I Accept

Reject All

Show Purpose

correlation with measures of QOL, but maximum exercise capacity was better correlated with lung function measures than 6-minute walk distance. After adjustment, 6MWD had a slightly greater association with total SGRQ score than maximal exercise (effect size 0.37 ± 0.04 vs. 0.25 ± 0.03 %predicted/unit). Despite advanced emphysema, patients are able to maintain 6MWD to a greater degree than maximum exercise capacity. Moreover, the 6MWT may be a better test of functional capacity given its greater association with QOL measures whereas CPX is a better test of physiologic impairment.

Key words: :

Emphysema Lung diseases obstructive Exercise tests Quality of life Clinical trial multicenter studies

INTRODUCTION

The 6-minute walk test (6MWT) measures the distance that an individual can walk in 6 minutes (6-minute walk distance, 6MWD) and was designed as a submaximal exercise test to re... currently it is widely u... of mortality ([2], [3])... resources and emp... y exercise testing (... ce and provides... h as maximum... ([4]). Com... subject to learning... en perform... walking. Choice of... is controver... gy of exercise... of function...



In general, measures of lung function have limited ability to predict exercise capacity in an individual. The forced expiratory volume in 1 second (FEV₁) is the most widely used lung function measurement to determine disease severity in COPD. However, a limitation of the FEV₁ is that it does not directly reflect the degree of static and dynamic hyperinflation in an individual with COPD. Recently, the development of dynamic hyperinflation with an increase in end-expiratory lung volume has been correlated with exercise limitation due to dyspnea ([7], [8], [9]). As inspiratory capacity (IC) is inversely related to end-expiratory lung volume, it is useful as a marker for lung hyperinflation. Reduced IC and IC/TLC ratio have been associated with poorer exercise performance and survival in COPD ([7], [10], [11]). Because of its relationship with dynamic hyperinflation, IC might be a better predictor of maximal exercise performance in COPD than FEV₁, but it is not known whether IC is a useful predictor of performance of the six-minute walk test.

The National Emphysema Treatment Trial (NETT) was a multicenter clinical trial comparing lung volume reduction surgery to medical treatment in individuals with advanced emphysema ([12]). During a comprehensive baseline evaluation, participants performed both 6MWT and CPX along with measures of lung function and quality of life. Using physiologic data collected during screening for the NETT, we compared these two types of exercise tests in individuals with advanced emphysema to determine the degree of dynamic hyperinflation. The CPX had a better correlation with lung function than the 6MWT. Both forms of exercise testing were associated with measures of lung function and quality of life.



Particip

Participa

multicen

treatme

included

capacity



smoking for four months prior to baseline screening and be free from severe co-morbid conditions. The trial design and main results have been previously published ([12], [13]). The research protocol was approved by the Institutional Review Boards of all participating institutions, and informed consent was obtained from participants prior to randomization.

Procedures

During the baseline evaluation and prior to initiation of pulmonary rehabilitation and randomization, participants performed a 6MWT and a maximum cycle ergometry exercise test within a 6-week period. Prior to the 6MWT, a treadmill test at 1-2 mph was performed to determine supplemental oxygen requirements during testing. The 6MWT was performed using a standard protocol using scripted prompts at 1-minute intervals. If oxygen supplementation was required during testing, a staff member walked behind the participant to carry the oxygen. Course layout and length varied by participating institution. Maximum walking distance, expressed as a percent predicted ([14]), was used for analysis.

Maximum symptom-limited CPX was performed on a bicycle ergometer with an increase in workload of either a 5 or 10 Watts at 1-minute intervals, based on the participant's maximum voluntary ventilation. Participants breathed 30% oxygen during the test exercise

Pulmonary centers Thoracic predicted

To evaluate (SF-36 Questionnaire obtained poorer health Alternatives specific 120 points



Statistical analysis

Baseline characteristics are presented as means and standard deviations for continuous variables and as frequencies and percentages for categorical variables. Scatter plots and Pearson correlation coefficients were used to determine the association between lung function, QOL scores, and exercise measures. Correlation coefficients were compared using the method of Meng et al. ([22]). Univariate regression models were developed for 6MWD and maximum work with SGRQ and FEV₁ in individual models. Multivariable linear regression models were then developed in a stepwise manner to estimate the magnitude and statistical confidence of the effect of FEV₁ and SGRQ Total Score on 6MWD and maximum exercise capacity, adjusting for age, gender, height, and weight. In order to use a similar metric for both 6MWD and maximum exercise capacity, both were analyzed as the percent of predicted value, calculated from literature values ([14], [15]). All statistics were performed using STATA software, version 8.2 (Stata Corporation; College Station, TX; 2004). P-values of less than 0.05 were considered statistically significant.



Results

Study population

The characteristics of the study population are presented in Table 1. The mean age of the participants was 62.1 ± 7.5 years. The mean FEV₁ was 1.8 L (217 mL below the normal range). The mean 6MWT was 360 m. The mean SGRQ score was 40.5. The mean hyperinflation score was 12.5. The mean group weight was 75.5 kg. The mean correlation coefficient between FEV₁ and 6MWT was 0.45. The mean correlation coefficient between FEV₁ and maximum exercise capacity was 0.35. Figure 1 shows the relationship between percent predicted FEV₁ and maximum exercise capacity. There was a positive correlation between percent predicted FEV₁ and maximum exercise capacity as shown in the scatter graph as



217
complete the
obstruction,
The study
significant
erable
Figure 2).
Panel A) and
m exercise
tendency.
on the



Display full size

Figure 2 Scatter plots of maximum exercise capacity (Watts) and 6-minute walk distance are correlated. The scatter plots show that as maximum exercise capacity increases, the 6-minute walk distance also tends to increase. The tests are

Six Minute Walk Distance (Feet)



Display full

Table 1 Participant characteristics (N = 1218)





Download CSV

Display Table

Impairment in maximum exercise capacity was greater than the 6-minute walk distance compared to reference values ($27.6 \pm 16.8\%$ predicted vs. $67.9 \pm 18.9\%$ predicted, $p < 0.001$). Moreover, the range of 6-minute walking distance was narrower and was more symmetrically distributed than maximum exercise capacity. The greater impairment in CPX compared to 6MWT is further illustrated by the fact that only 12 participants (1.0%) had a maximum exercise capacity greater than 80% predicted. In contrast, 308 (25.3%) of the study group had a 6-minute walk distance that was greater than 80% predicted. Alternatively, 34% of individuals had a maximum exercise capacity less than 20% predicted compared to only 2 (0.2%) of individuals who had a 6MWD less than 20% predicted. Additionally, 4.8% were unable to perform more than 5 watts of exercise compared to only 1.2% of the subjects who could walk no more than 500 feet, values that have previously been associated with poorer outcomes in COPD ([3], [23]).

The correlations between 6MWD, exercise capacity, and measures of pulmonary function are shown in Table 2 and Figure 3A and Figure 3B. The best correlates of exercise capacity were FEV₁ (partial correlation coefficient = 0.65), maximum exercise capacity (partial correlation coefficient = 0.65). The correlation between 6MWD and maximum exercise capacity was weak (partial correlation coefficient = 0.38). The correlation between 6MWD and SGRQ was moderate (partial correlation coefficient = 0.38). The correlation between maximum exercise capacity and SGRQ was moderate (partial correlation coefficient = 0.38). The correlation between maximum exercise capacity and maximum exercise capacity was moderate (partial correlation coefficient = 0.38). The correlation between maximum exercise capacity and maximum exercise capacity was moderate (partial correlation coefficient = 0.38).





Display full size

Table
Tests

Download

×



es of quality
hilarly
ce. By
nce in SGRQ

(Panel A)
blains
exercise

DISCUSSION

This study demonstrates that 6MWD and CPX, although significantly correlated, measure somewhat different domains of exercise performance in individuals with advanced emphysema. When results are expressed as percent of predicted, these individuals with severe emphysema have less impairment of the 6MWD than impairment of maximum exercise capacity. Indeed, despite a mean FEV₁ % predicted of 26.9%, participants achieved a mean of 68% predicted 6MWD and had remarkable preservation of their endurance given the degree of lung function impairment. Individuals with COPD, in general, exercise at a higher fraction of their maximum exercise capacity than normal individuals ([24]). Thus, we interpret these findings to indicate that individuals with severe lung function impairment can maintain walking distance through the use of submaximal ventilation that approaches but does not exceed their maximum sustainable ventilation. This is analogous to the relative preservation of submaximal exercise capacity relative to maximum exercise capacity that is seen in elderly individuals ([25]).

Performance on both exercise tests is correlated with ventilatory impairment indicated by standard lung function tests, particularly the FEV₁ and IC. However, maximum exercise capacity is not significantly correlated with maximum minute ventilation. This is consistent with previous findings ([26], [27], [28]). Our findings suggest that the day-to-day variability in exercise performance is not explained by other haemodynamic or physiological factors. Supplemental oxygen may be a factor that improves exercise performance in individuals with severe COPD. On the basis of our findings, we recommend that individuals with severe COPD be given supplemental oxygen during walking distance tests rather than during maximum exercise capacity tests.



hypoxemia, we might have found better correlation of exercise capacity with diffusing capacity ([29]).

In univariate analysis, both the 6MWT and CPX were similarly correlated with quality of life measures as has been reported previously in the NETT population ([30]).

Presumably, the impact of disease on daily activities is more closely related to the submaximal exercise of the 6MWT than by maximum exercise tests. Previously, the NETT investigators have reported that the SOBQ was slightly better in predicting both maximum exercise capacity and 6MWD than the SGRQ ([30]). However, both SOBQ and SGRQ were well correlated with each other ($r = 0.67$, $p < 0.0001$) suggesting that they measure similar features of the impact of respiratory disease. In contrast, the generic health-related QOL instrument, the SF-36 physical component summary, did not have a strong association with either exercise test.

Previous studies that have directly compared the measurement properties of the 6MWT and the CPX have shown variable results ([6]). There is a significant correlation between maximum oxygen consumption and 6MWD ($r = 0.51$) ([31]) and between maximum oxygen consumption and maximum work ($r = 0.58-0.81$) ([5], [32]).

However, few studies have directly compared the results of the 6MWT and the CPX to their relationship with lung function and QOL measures. Wijkstra, et al, showed no significant difference in the correlation of lung function (FEV₁, P_V, D_{CO}) with the CPX

and 6MWD. However, the 6MWD had a stronger correlation with Borg Dyspnea score than measured by the Borg Dyspnea score.

The primary aim of this study was to compare the measurement properties of maximum exercise capacity and 6MWD. The study was designed to evaluate both the physiological and clinical validity of these tests. The study was designed to evaluate both the physiological and clinical validity of these tests.

The primary aim of this study was to compare the measurement properties of maximum exercise capacity and 6MWD. The study was designed to evaluate both the physiological and clinical validity of these tests.

The primary aim of this study was to compare the measurement properties of maximum exercise capacity and 6MWD. The study was designed to evaluate both the physiological and clinical validity of these tests.

The primary aim of this study was to compare the measurement properties of maximum exercise capacity and 6MWD. The study was designed to evaluate both the physiological and clinical validity of these tests.



One of the strengths of this study is that it represents a large group of individuals with lung disease well-characterized as emphysema. Because the study was done at 17 clinical centers, it is likely to be more generally representative than studies done at a single center. However, we are cautious about extending the results from this study to those with less severe COPD as the study population was limited to a narrow range of individuals with severe or very severe emphysema who were participating in a trial of lung volume reduction surgery. In addition, the CPX was performed while individuals were receiving 30% inspired oxygen, which is not a standard practice. Delivery of a fixed concentration of oxygen may not be feasible in many laboratories, and some individuals may have better maximum exercise performance while performing CPX on oxygen.


In conclusion, we have found that the 6MWT and CPX, although correlated with each other, measure different aspects of exercise capacity. The CPX better reflects aspects of both lung function and is more severely impaired by emphysema, whereas the 6MWT is more closely related to functional impairment in activities of daily life and is less impaired in severe emphysema.

ACKNOWLEDGMENTS

The members of the research team who were as follows: Pennsylvania, Philadelphia, and the University of Pennsylvania School of Medicine. Chatziioannou, C. Nguyen, R. Butcher, C. M. Moore, Women's Health, Forman, Peterson, Angeles, Lewis, J. DeCamp, were as follows: Pennsylvania, Philadelphia, and the University of Pennsylvania School of Medicine. Chatziioannou, C. Nguyen, R. Espada, n, K. King, Brigham and Women's Hospital, Boston, MA; Puffy, V. Moy, S. Los Angeles, CA; P. Julien, M. Cleveland: M. , R. Dweik,



Meziane, O. Minai, P. O'Donovan, M. Steiger, K. White, J. Maurer, C. Hearn, S. Lubell, R. Schilz, T. Durr; Columbia University, New York, and Long Island Jewish Medical Center, New Hyde Park, N.Y.: M. Ginsburg, B. Thomashow, P. Jellen, J. Austin, M. Bartels, Y. Berkman, P. Berkoski, F. Brogan, A. Chong, G. DeMercado, A. DiMango, B. Kachulis, A. Khan, B. Mets, M. O'Shea, G. Pearson, J. Pfeffer, L. Rossoff, S. Scharf, M. Shiau, P. Simonelli, K. Stavrolakes, D. Tsang, D. Vilotijevic, C. Yip, M. Mantinaos, M. McKeon; Duke University Medical Center, Durham, N.C.: N. MacIntyre, R.D. Davis, J. Howe, R.E. Coleman, R. Crouch, D. Greene, K. Grichnik, D. Harpole, A. Krichman, B. Lawlor, H. McAdams, J. Plankeel, S. Rinaldo-Gallo, J. Smith, M. Stafford-Smith, V. Tapson, M. Steele, J. Norten; Mayo Foundation, Rochester, Minn.: J. Utz, C. Deschamps, K. Mieras, M. Abel, M. Allen, D. Andrist, G. Aughenbaugh, S. Bendel, E. Edell, M. Edgar, B. Edwards, B. Elliot, J. Garrett, D. Gillespie, J. Gurney, B. Hammel, K. Hanson, L. Hanson, G. Harms, J. Hart, T. Hartman, R. Hyatt, E. Jensen, N. Jenson, S. Kalra, P. Karsell, D. Midthun, C. Mottram, S. Swensen, A.-M. Sykes, K. Taylor, N. Torres, R. Hubmayr, D. Miller, S. Bartling, K. Bradt; National Jewish Medical and Research Center, Denver: B. Make, M. Pomerantz, M. Gilmartin, J. Canterbury, M. Carlos, P. Dibbern, E. Fernandez, L. Geyman, C. Hudson, D. Lynch, J. Newell, R. Quaife, J. Propst, C. Raymond, J. Whalen-Price, K. Winner, M. Zamora, R. Cherniack; Ohio State University, Columbus: P. Diaz, P. Ross, T. Bees, H. Awad, J. Drake, C. Emery, M. Gerhardt, M. Kelsey, M. King, D. Rittinger, M. Rittinger; Saint Louis University, St. Louis: K. Naunheim, F. Alvarez, J. Osterloh, S. Borosh, J. Solar, J. Willey, C. M. Kuzma, R. Barnette, K. ztury, K. Kirsch, C. , J. Travaline, o, San Diego: A. Johnson, D. Kapelan, ofanis, D. Sass, and Johns Hopki. Orens, S. Scharf, D. chigan, Ann Arbor: F. ensen, K. Flaherty, e, L. Quint, P. Rysso, T. nia, Philadel, o, J. Aronchi, Geffer, I.



Sheaffer, R. Simcox, S. Snedeker, J. Stone-Wynne, G. Tino, P. Wahl, J. Walter, P. Ward, D. Zisman, J. Mendez, A. Wurster; University of Pittsburgh, Pittsburgh: F. Sciorba, J. Luketich, C. Witt, G. Ayres, M. Donahoe, C. Fuhrman, R. Hoffman, J. Lacomis, J. Sexton, W. Slivka, D. Stollo, E. Sullivan, T. Simon, C. Wrona, G. Bauldoff, M. Brown, E. George, R. Keenan, T. Kopp, L. Silfies; University of Washington, Seattle: J. Benditt, D. Wood, M. Snyder, K. Anable, N. Battaglia, L. Boitano, A. Bowdle, L. Chan, C. Chwalik, B. Culver, T. Gillespy, D. Godwin, J. Hoffman, A. Ibrahim, D. Lockhart, S. Marglin, K. Martay, P. McDowell, D. Oxorn, L. Roessler, M. Toshima, S. Golden.

Other participants included the following: Agency for Healthcare Research and Quality, Rockville, Md.: L. Bosco, Y.-P. Chiang, C. Clancy, H. Handelsman; Centers for Medicare and Medicaid Services, Baltimore: S. Sheingold, T. Carino, J. Chin, J. Farrell, K. McVearry, A. Norris, S. Shirey, C. Sikora; Coordinating Center, Johns Hopkins University, Baltimore: S. Piantadosi, J. Tonascia, P. Belt, K. Collins, B. Collison, J. Dodge, M. Donithan, V. Edmonds, J. Fuller, J. Harle, R. Jackson, H. Koppelman, S. Lee, C. Levine, H. Livingston, J. Meinert, J. Meyers, D. Nowakowski, K. Owens, S. Qi, M. Smith, B. Simon, P. Smith, A. Sternberg, M. Van Natta, L. Wilson, R. Wise; Cost-Effectiveness Subcommittee: R.M. Kaplan, J.S. Schwartz, Y-P. Chiang, M.C. Fahs, A.M. Fendrick, A.J. Moskowitz, D. Pathak, S. Ramsey, S. Sheingold, A.L. Shroyer, J. Wagner, R. Yusen; Cost-Effectiveness Data Center, Fred Hutchinson Cancer Research Center, Seattle: S. Ramsey, R. Etzioni, S.

Sullivan, and Ana Delsing, Data and Ferguson Williams Soltoff; F Weinp Other Lakewood Funding: (N01HR7 N01HR7 N01HR7



REFERENCES

1. Butland R J, Pang J, Gross E R, Woodcock A A, Geddes D M. Two-, six-, and 12-minute walking tests in respiratory disease. *Br Med J (Clin Res Ed)* 1982; 284(6329)1607-1608

 PubMed

 Web of Science ®

 Google Scholar

2. ATS. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166(1)111-117

 PubMed

 Web of Science ®

 Google Scholar

3. Celli B R, Cote C G, Marin J M, Casanova C, Montes de Oca M, Mendez R A, Pinto Plata V, Cabral H J. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in a population-based study. *Am J Respir Crit Care Med* 2004; 170(1)350(1)



4. ATS. A statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166(1)111-117



5. Guyatt G H, Pugsley L, S O. H. Lung disease

6. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. *Chest* 2001; 119(1)256-270

 PubMed

 Web of Science ®

 Google Scholar

7. Diaz O, Villafranca C, Ghezzi H, Borzone G, Leiva A, Milic-Emil J, Lisboa C. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. *Eur Respir J* 2000; 16(2)269-275

 PubMed

 Web of Science ®

 Google Scholar

8. O'Donnell D E, Revill S M, Webb K A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 164(5)770-777

 PubMed

 Web of Science ®

 Google Scholar

9. O'Donnell D E, Webb K A. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. *Am Rev Respir Dis* 1993; 148(5)1351-1357

 PubMed

 Web of Science ®

 Google Scholar

10. Casanovi A, et al. Inspiratory capacity and exercise tolerance in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 164(5)591-597

11. O'Donnell D E, et al. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 164(5)770-777

12. The National Lung Health Survey. The National Lung Health Survey: design of the study and results of lung function measurements. *Am J Respir Crit Care Med* 1995; 151(4)1151-1160

PubMed

Web of Science®

Google Scholar

3. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood D E. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* 2003; 348(21)2059-2073

PubMed

Web of Science®

Google Scholar

4. Enright P L, Sherrill D L. Reference equations for the six-minute walk in healthy adults. *Am J Respir Crit Care Med* 1998; 158: 1384-1387, (5 Pt 1)

Updates

PubMed

Web of Science®

Google Scholar

5. Jones N L, Summers E, Killian K J. Influence of age and stature on exercise capacity during incremental cycle ergometry in men and women. *Am Rev Respir Dis* 1989; 140(5)1373-1380

PubMed

Web of Science®

Google Scholar

6. Crapo R O, Morris A H. Standardized single breath normal values for carbon monoxide diffusing capacity. *Am Rev Respir Dis* 1981; 123(2)185-189

PubMed



7. Crapo R O, Morris A H. Standardized single breath normal values for carbon monoxide diffusing capacity in healthy adults. *Am Rev Respir Dis* 1981; 123(2)185-189

PubMed

8. Crapo R O, Morris A H. Standardized single breath normal values for carbon monoxide diffusing capacity in healthy adults. *Am Rev Respir Dis* 1981; 123(2)185-189

PubMed

9. Eakin M P, et al. The effect of a new...
dyspnea...
of



PubMed

Web of Science®

Google Scholar

20. Jones P W, Quirk F H, Baveystock C M, Littejohns P A. A self-complete measure of health status for chronic airflow limitation. *Am Rev Respir Dis* 1992; 145: 1321-1327

PubMed

Web of Science®

Google Scholar

21. Ware J, Snow K, Kosinski M. G. B. SF-36 health survey: manual and interpretation guide. The Health Institute, New England Medical Center, Boston 1993

Google Scholar

22. Meng X, Rosenthal R, Rubin D. Comparing correlated correlation coefficients. *Psychol Bull* 1992; 111(1)172-175

Web of Science®

Google Scholar

23. Bowen J B, Votto J J, Thrall R S, Haggerty M C, Stockdale-Woolley R, Bandyopadhyay T, ZuWallack R L. Functional status and survival following pulmonary rehabilitation. *Chest* 2000; 118(3)697-703

PubMed

Web of Science®

Google Scholar

24. Neder... endurance
capac... er-duration
relatio...

25. Pos... rement and
val...

PubMed

26. Carter... mal
exerci... se. *Chest*
1987;



27. Fink G, Lebzelter J, Turner D, Klainman E, Shlomo M, Katz I, Kramer M, Spitzer S. Pulmonary function threshold for distinguishing ventilatory- and nonventilatory-limited patients with airflow obstruction. *Respir Med* 1998; 92(10)1245-1250

 PubMed

 Web of Science ®

 Google Scholar

28. LoRusso T J, Belman M J, Elashoff J D, Koerner S K. 1993. Prediction of maximal exercise capacity in obstructive and restrictive pulmonary disease. *Chest* 1993; 104(6)1748-1754

 PubMed

 Web of Science ®

 Google Scholar

29. Owens G R, Rogers R M, Pennock B E, Levin D. The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease. *N Engl J Med* 1984; 310(19)1218-1221

 PubMed

 Web of Science ®

 Google Scholar

30. Kaplan R M, Ries A L, Reilly J, Mohsenifar Z. Measurement of health-related quality of life in the national emphysema treatment trial. *Chest* 2004; 126(3)781-789

 PubMed

 Web of Science ®

 Google Scholar

31. Bernstein A, et al. Reanalysis of the... disease. *Chest* 1994;

32. Wil... Kraan J, Ko... noea, and quality... pulmonary disease

33. Pitta F... ntifying



Download PDF

Related research

People also read

Recommended articles

Cited by
44

Severe Chronic Bronchitis in Advanced Emphysema Increases Mortality and Hospitalizations >

Victor Kim et al.

COPD: Journal of Chronic Obstructive Pulmonary Disease

Published online: 26 Aug 2013

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 >

Daniel J. Klionsky et al.

Autophagy

Published

Guidelines

Daniel J

Autophagy

Published



Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books



Copyright

Accessib

Registered
5 Howick Pl

or & Francis Group
orma business

